Bicycle therapeutics reports recent business progress and third quarter 2025 financial results

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today reported financial results for the third quarter ended september 30, 2025, and provided recent corporate updates. “we are currently seeking broad regulatory feedback to make an informed decision on our path forward with zelenectide pevedotin in metastatic ur.
BCYC Ratings Summary
BCYC Quant Ranking